Details

Autor(en) / Beteiligte

• Leung, Alexander A., MD MPH
• Daskalopoulou, Stella S., MD PhD
• Dasgupta, Kaberi, MD MSc
• McBrien, Kerry, MD MPH
• Butalia, Sonia, BSc MD
• Zarnke, Kelly B., MD MSc
• Nerenberg, Kara, MD MSc
• Harris, Kevin C., MD MHSc
• Nakhla, Meranda, MD MSc
• Cloutier, Lyne, RN PhD
• Gelfer, Mark, MD
• Lamarre-Cliche, Maxime, MD
• Milot, Alain, MD MSc MD
• Bolli, Peter, MD
• Tremblay, Guy, MD
• McLean, Donna, RN NP PhD
• Tobe, Sheldon W., MD MSc(HPTE)
• Ruzicka, Marcel, MD PhD
• Burns, Kevin D., MD
• Vallée, Michel, MD PhD
• Prasad, G. V. Ramesh, MBBS MSc
• Gryn, Steven E., MD
• Feldman, Ross D., MD
• Selby, Peter, MBBS MHSc
• Pipe CM, Andrew, MD
• Schiffrin, Ernesto L., MD PhD
• McFarlane, Philip A., MD PhD
• Oh, Paul, MD
• Hegele, Robert A., MD
• Khara, Milan, MBChB
• Wilson, Thomas W., MD
• Penner, S. Brian, MD
• Burgess, Ellen, MD
• Sivapalan, Praveena, MD
• Herman, Robert J., MD
• Bacon, Simon L., PhD
• Rabkin, Simon W., MD
• Gilbert, Richard E., MD PhD
• Campbell, Tavis S., PhD
• Grover, Steven, MD MPA
• Honos, George, MD
• Lindsay, Patrice, RN PhD
• Hill, Michael D., MD MSc
• Coutts, Shelagh B., MD
• Gubitz, Gord, MD
• Campbell, Norman RC., MD
• Moe, Gordon W., MD MSc
• Howlett, Jonathan G., MD
• Boulanger, Jean-Martin, MD
• Prebtani, Ally, MD
• Kline, Gregory, MD
• Leiter, Lawrence A., MD
• Jones, Charlotte, MD PhD
• Côté, Anne Marie, MD MHSc
• Woo, Vincent, MD
• Kaczorowski, Janusz, PhD
• Trudeau, Luc, MD
• Tsuyuki, Ross T., BSc (Pharm) PharmD MSc
• Hiremath, Swapnil, MD MPH
• Drouin, Denis, MD
• Lavoie, Kim L., PhD
• Hamet, Pavel, MD PhD
• Grégoire, Jean C., MD
• Lewanczuk, Richard, MD PhD
• Dresser, George K., MD PhD
• Sharma, Mukul, MD MSc
• Reid, Debra, PhD DtP
• Lear, Scott A., PhD
• Moullec, Gregory, PhD
• Gupta, Milan, MD
• Magee, Laura A., MD MSc
• Logan, Alexander G., MD
• Dionne, Janis, MD
• Fournier, Anne, MD
• Benoit, Geneviève, MD
• Feber, Janusz, MD
• Poirier, Luc, BPharm MSc
• Padwal, Raj S., MD MSc
• Rabi, Doreen M., MD MSc

Titel

Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults

Ist Teil von

• Canadian journal of cardiology, 2017-05, Vol.33 (5), p.557-576

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2017

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Hypertension Canada provides annually-updated, evidence-based guidelines for the diagnosis, assessment, prevention, and treatment of hypertension. This year, we introduce 10 new guidelines. Three previous guidelines have been revised and 5 have been removed. Previous age and frailty distinctions have been removed as considerations for when to initiate antihypertensive therapy. In the presence of macrovascular target organ damage, or in those with independent cardiovascular risk factors, antihypertensive therapy should be considered for all individuals with elevated average systolic blood pressure readings ≥140 mmHg. For individuals with diastolic hypertension (with or without systolic hypertension), fixed-dose single pill combinations are now recommended as an initial treatment option. Preference is given to pills containing an angiotensin converting enzyme inhibitor or angiotensin receptor blocker in combination with either a calcium channel blocker or diuretic. Whenever a diuretic is selected as monotherapy, longer-acting agents are preferred. In patients with established ischemic heart disease, caution should be exercised in lowering diastolic pressure ≤60 mmHg, especially in the presence of left ventricular hypertrophy. Following a hemorrhagic stroke, in the first 24 hours, systolic blood pressure lowering to <140 mmHg is not recommended. Finally, guidance is now provided for screening, initial diagnosis, assessment, and treatment of renovascular hypertension arising from fibromuscular dysplasia. The specific evidence and rationale underlying each of these guidelines are discussed.